Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
$0.32 per share
Est. EPS $0.44 · Revenue $292.06M · 5 analysts
Est. EPS $0.48 · Revenue $308.37M · 4 analysts
Est. EPS $0.56 · Revenue $328.16M · 1 analysts
$0.32 per share
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $1.2B | -0.4% | +3.1% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $181.9M | +147.8% | +7.0% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +65.8% | +1.5% | -1.6% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | +20.7% | +147.3% | -4.6% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | +15.0% | +148.7% | +3.7% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $263.2M | +2.6% | +12.1% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | +21.7% | +3.0% | +8.7% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 13.7% | -40.7% | -1.5% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 4.55x | +31.5% | +1.3% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $2.7B | +4.7% | +1.4% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | 1.16 vs 1.92 | -39.7% | 0.36 vs 0.44 | -18.2% |
| Revenue Surprise | $1.2B vs $1.2B | +0.7% | $321.2M vs $292.1M | +10.0% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Bohnen Shane | officer: SVP - General Counsel | Restricted Stock Units | A | 18,432 | — |
| Aug 17, 2026 | Bohnen Shane | officer: SVP - General Counsel | Restricted Stock Units | A | 11,344 | — |
| Aug 17, 2026 | Kelderman Kim | director, officer: Chief Executive Officer | Restricted Stock Units | A | 93,582 | — |
| Aug 17, 2026 | Kelderman Kim | director, officer: Chief Executive Officer | Restricted Stock Units | A | 57,590 | — |
| Aug 17, 2026 | Hippel James | officer: CFO | Restricted Stock Units | A | 36,459 | — |
Operator: Good morning, and welcome to the Bio-Techne Earnings Conference Call for the Third Quarter and Fiscal Year 2026. [Operator Instructions] I would now like to turn the call over to David Clair, Bio-Techne's Vice President, Investor Relations. Please go ahead. David Clair: Good morning, and thank you for joining us. On the call with me this morning are Kim Kelderman, President and Chief Executive Officer; and Jim Hippel, Chief Financial Officer of Bio-Techne. Before we begin, let me briefly cover our safe harbor statement. Some of the comments made during this conference call may be considered forward-looking statements, including beliefs and expectations about the company's future results. The company's 10-K for fiscal 2025 identifies certain factors that could cause the company's actual results to differ materially from those projected in the forward-looking statements made during this call. The company does not undertake to update any forward-looking statements because of any new information or future events or developments. The 10-K as well as the company's other SEC filings are available on the company's website within its Investor Relations section. During the call, non-GAAP financial measures may be used to provide information pertinent to ongoing business performance. Tables reconciling these measures to most comparable GAAP measures are available in the company's press release issued earlier this morning on the Investor Relations section of our Bio-Techne Corporation website at www.bio-techne.com. Separately, in the coming weeks, we will be participating in the Bank of America and Jefferies Healthcare Conferences. We look forward to connecting with many of you at these upcoming events. I will now turn the call over to Kim. Kim Kelderman: Thank you, Dave, and good morning, everyone. Welcome to Bio-Techne's Third Quarter Earnings Call for Fiscal 2026. The Bio-Techne team continued to execute with discipline in a dynamic and uneven end market environment. Our quarterly performance was supported by sustained strength from our large pharmaceutical customers and stable to improving trends in our U.S. academic end market. These positives were partially offset by continued softness in emerging biotech spending, resulting in a 2% organic revenue decline for the quarter. Importantly, we are seeing encouraging indicators that point to an ongoing improvement in the U.S. academia and an eventual recovery in emerging biotech, which positions us well for a stronger fiscal 2027. As discussed in our prior earnings call, order timing related to 2 cell therapy customers that received FDA Fast Track Designation along with the timing of a large OEM commercial supply order created a 400 basis point headwind in the quarter. Excluding these factors, underlying organic revenue growth was 2%. There were several notable highlights during our third quarter, including the following: our Spatial Biology portfolio delivered mid-teens growth and exited the …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Kim Kelderman | Chief Executive Officer, President & Director | USD 2,288,390 | Male | 1968 | Active |
James T. Hippel | Executive Vice President of Finance & Chief Financial Officer | USD 1,667,089 | Male | 1971 | Active |
William A. Geist | President of Protein Sciences Segment | USD 1,339,266 | Male | 1969 | Active |
Shane Bohnen | Senior Vice President, General Counsel, Corporate Secretary & Chief Sustainability Officer | USD 835,661 | Male | 1976 | Active |
Gerry Andros | Vice President of Sales and Marketing | — | Male | — | Active |
Luca Cicchetti | Managing Director | — | Male | — | Active |
Martin Wirtz | Senior Vice President of Strategy & Corporate Development | — | Male | — | Active |
Steve Crouse | President of Diagnostics & Spatial Biology Segment | — | Male | 1973 | Active |
Dylan Malayter | Senior Vice President of Reagent Solutions Division | — | Male | — | Active |
Cheryl Bethune | Senior Vice President & Chief Human Resources Officer | — | Female | — | Active |
David Clair | Vice President of Investor Relations | — | Male | — | Active |
Bernie Andruss | Senior Vice President of Bio-Techne Diagnostics Division | — | — | — | Active |
Gary J. Latham | Vice President & Chief Technology Officer | — | — | — | Active |
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Jazz Pharmaceuticals (JAZZ) and Techne (TECH). But which of these two stocks presents investors with the better value opportunity right now?
California State Teachers Retirement System lifted its position in Bio-Techne Corp (NASDAQ: TECH) by 24.1% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 184,164 shares of the biotechnology company's stock after purchasing an additional 35,772 shares during the quarter. California State
CMB.TECH FLEET UPDATE ANTWERP, Belgium, 3 August 2026, 08:00 CET – CMB.TECH NV (“CMBT”, “CMB.TECH” or “the company”) (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) has sold one VLCC, generating a capital gain of approximately 74.4 million USD. Euronav CMB.TECH has sold the VLCC Donoussa (2016, 299,999 dwt).
FHLC's 0.08% expense ratio and market-cap approach delivered stronger returns, while RSPH's equal-weight strategy offers lower volatility and broader diversification across 60 holdings.
The top five contributors for the quarter were MKS, Amphenol, Arista Networks, Bio-Techne, and Waters. The bottom five detractors for the quarter were Ross Stores, Arch Capital, Copart, Gartner, and Brown & Brown. We purchased shares in Verisk Analytics, the dominant provider of data and analytics to property and casualty insurers in the U.S.
